Background/Aims Maternal and fetal outcomes in pregnant patients with Non-alcoholic fatty liver disease (NAFLD) have been largely unexplored. To determine the level of evidence associated with maternal and fetal outcomes in pregnant women with NAFLD.
Methods We conducted a comprehensive literature search. The studies included pregnant patients with a previous, current or subsequent diagnosis of NAFLD. We used a random-effects model using odds ratios (OR) with 95% confidence intervals (CI).
Results Twenty-two studies, with 13,641 female NAFLD patients were reviewed. The results highlight that NAFLD patients had a statistically significant increased likelihood of baseline diabetes mellitus (OR, 6.00; 95% CI, 2.21–16.31; P<0.001; n=7), baseline Hypertension (OR, 3.75; 95% CI, 2.13–6.59; P<0.001; n=4), gestational hypertension (OR, 1.83; 95% CI, 1.03–3.26; P=0.041; n=2), and pre-eclampsia (OR, 2.43; 95% CI, 1.46–4.04; P=0.001; n=3). The odds for a past and current history of gestational diabetes mellitus were OR, 3.78; 95% CI, 2.21–6.44; P<0.001; n=5 and OR, 3.23; 95% CI, 1.97– 5.31; P<0.001; n=6, respectively. As for fetal outcomes, pregnant NAFLD patients were significantly more likely to have a premature birth (OR, 2.02; 95% CI, 1.44–2.85; P<0.001; n=4), large for gestational age birth (OR, 2.01; 95% CI, 1.72–2.37; P<0.001; n=2) or a history of prior miscarriage or abortion (OR, 1.15; 95% CI, 1.02–1.30; P=0.02; n=2). Egger’s regression revealed no evidence of publication bias (P>0.05).
Conclusions This meta-analysis provides pooled evidence that NAFLD is associated with a substantial increase in maternal diabetic and hypertensive complications and multiple adverse fetal outcomes. This data is important for clinicians managing these patients before, during and after pregnancy.
Citations
Citations to this article as recorded by
Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations Diego F. Wyszynski Journal of Clinical and Experimental Hepatology.2026; 16(2): 103431. CrossRef
Evaluating metabolic dysfunction-associated steatotic liver disease, associated adverse pregnancy outcomes, and postpartum maternal course utilising transient elastography with controlled attenuation parameter in pregnancy: a prospective cohort study Marcia Lange, Jeanette Rios, Cecilia Katzenstein, Theresa Worthington, Carin Carroll, Nina Rodriguez, Rachel Meislin, Pamela Argiriadi, Sonam Rosberger, Emma Rosenbluth, Rhoda Sperling, Keith Sigel, Norah A Terrault, Tatyana Kushner The Lancet Obstetrics, Gynaecology, & Women's Health.2026; 2(1): e33. CrossRef
Higher Risk of Serious Infection in Offspring of Mothers With Biopsy‐Proven MASLD: A Nationwide Cohort Study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson United European Gastroenterology Journal.2026;[Epub] CrossRef
Neither Metabolic Dysfunction Associated Steatotic Liver Disease Presence Nor Fibrosis Severity, By FIB4, Predicts Adverse Pregnancy Outcomes Christine Lopez, Zoe Finer, Suzanne Sharpton, Rolanda Lister, Jennifer Thompson, Christopher Lindsell, Yue Gao, Hillary Duckham, Manhal Izzy Journal of Clinical Gastroenterology.2026;[Epub] CrossRef
Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study Rong Shuai, Yuxing He, Dongqian Yang, Yingying Zhang, Li Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
GDM-BC: Non-invasive body composition dataset for intelligent prediction of Gestational Diabetes Mellitus Chen Zheng, Tong Qing, Mao Li, Shujuan Liao, Biru Luo, Chenwei Tang, Jiancheng Lv Computers in Biology and Medicine.2025; 192: 110176. CrossRef
Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson eClinicalMedicine.2025; 83: 103238. CrossRef
Global burden of metabolic disorders among women of child-bearing age, 1990–2021: a population-based study Junyu Chen, Dihan Fu, Tianqi Ma, Minghong Chen, Xuerui Wang, Jun Yi BMC Women's Health.2025;[Epub] CrossRef
Metabolic dysfunction–associated steatotic liver disease and pregnancy Monika Sarkar, Tatyana Kushner Journal of Clinical Investigation.2025;[Epub] CrossRef
The Maternal and Fetal Consequences of Metabolic Dysfunction-Associated Fatty Liver Disease and Gestational Diabetes Mellitus Thora Y. Chai, Jacob George, Dharmintra Pasupathy, Ngai Wah Cheung, Victoria L. Rudland Nutrients.2025; 17(10): 1730. CrossRef
Associations of hepatic steatosis index in early pregnancy with perinatal outcomes: A prospective birth cohort study Shaofei Su, Enjie Zhang, Shen Gao, Yue Zhang, Jianhui Liu, Shuanghua Xie, Jinghan Yu, Qiutong Zhao, Wentao Yue, Ruixia Liu, Chenghong Yin Clinical Medicine.2025; 25(4): 100343. CrossRef
Mortality and Cancer in Offspring of Mothers With Biopsy‐Proven MASLD During Pregnancy: A Nationwide Cohort Study Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson Liver International.2025;[Epub] CrossRef
Global, regional, and national time trends in prevalence of metabolic dysfunction associated steatotic liver disease among women of reproductive age: an age-period-cohort analysis for the global Burden of Disease 2021 study Jiehua Wei, Shanyu Lin, Senmao Zhang, Luying Fan, Lisa Jiang, Fan Xia, Ziye Li, Lizhang Chen, Zhiyong Zou, Tingting Wang Annals of Medicine.2025;[Epub] CrossRef
Biomarker discovery in NAFLD: insights from metabolomics and vote counting meta-analysis Pallavi Mudgal, Sonu Kumar Gupta, Sunny Malik, Rinkal B. Nith, Sunil Kumar, Rahul K, Kartikey Chaturvedi, Yashwant Kumar Metabolomics.2025;[Epub] CrossRef
Liver diseases in pregnancy: Clinical spectrum and outcomes – A review Sunita Khanam, Manisha Gupta, Alpana Agrawal, Ashok Kumar Kumar Santosh University Journal of Health Sciences.2025; 11(1): 156. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Pregnancy Hannah W. Han, Peter S. Marcus, Tse-Ling Fong Obstetrical & Gynecological Survey.2025; 80(10): 647. CrossRef
Влияние неалкогольной жировой болезни печени на течение беременности и неонатальные исходы: обзор литературы
Виталий Анатольевич Резник, Юрий Павлович Успенский, Полина Юрьевна Бухмирова, Александр Александрович Гнутов, Виталий Антонович Добренко University therapeutic journal.2025; 7(3): 7. CrossRef
Relationship between MASLD and women’s health: A review Pavlina Jancova, Khaled Ismail, Lucie Vistejnova Women's Health.2025;[Epub] CrossRef
Maternal metabolic dysfunction-associated steatotic liver disease during pregnancy and its impact on offspring steatosis Corie M. Klepper, Andrew T. Trout, Shun Dong, Lin Fei, Traci E. Stankiewicz, Jennifer Wayland, Maria E. Moreno-Fernandez, Senad Divanovic, Stavra A. Xanthakos, Emily DeFranco, Jessica G. Woo, Marialena Mouzaki Clinical Nutrition ESPEN.2025; 70: 327. CrossRef
What role does metabolic disfunction-associated fatty liver disease play in the metabolic landscape of pregnancy? Annunziata Lapolla, Maria Grazia Dalfrà Expert Review of Endocrinology & Metabolism.2025; : 1. CrossRef
Non-genetic risk factors of miscarriage: a comprehensive umbrella review of systematic review and meta-analysis Maedeh Arshadi, Mohammad Hasan Lotfi, Farzan Madadizadeh, Atiyeh javaheri, Moslem Taheri Soodejani Reproductive Health.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease and adverse pregnancy outcomes: a nationwide cohort study Young Mi Jung, Taesu Kim, Min-Jeong Oh, Dong Hyeon Lee, Geum Joon Cho, Won Kim Hepatology International.2025;[Epub] CrossRef
Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions Mohamad Jamalinia, Samira Saeian, Nima Nikkhoo, Amirhossein Nazerian, Kamran Bagheri Lankarani Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Evaluating the 2023 European Association for the Study of the Liver Guidelines for Intrahepatic Cholestasis of Pregnancy: Risk Stratification and Outcomes in Over 4,000 US Patients Nina Rodriguez, Cecilia Katzenstein, Lauren Alpert, Keith Sigel, Rhoda S. Sperling, Catherine Williamson, Tatyana Kushner American Journal of Gastroenterology.2025;[Epub] CrossRef
Hepatocyte ballooning and steatosis in early and late gestation without liver malfunction: Effects of low protein/high carbohydrate diet Mónica Navarro-Meza, Mauricio Díaz-Muñoz, José Alfonso Cruz-Ramos, Jonathan Rafael Trinidad Gallardo, María Conchita Rodríguez Oseguera, Paola C. Bello-Medina, Ericka Alejandra De Los Ríos-Arellano, Rajesh Yetirajam PLOS ONE.2024; 19(1): e0294062. CrossRef
Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study Young Mi Jung, Seung Mi Lee, Wonyoung Wi, Min-Jeong Oh, Joong Shin Park, Geum Joon Cho, Won Kim JHEP Reports.2024; 6(4): 101033. CrossRef
Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study Ben-Gang Zhou, Jian-Lei Xia, Xin Jiang, Yan-Bing Ding, Qiang She BMC Endocrine Disorders.2024;[Epub] CrossRef
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros Pharmacological Reviews.2024; 76(3): 454. CrossRef
Maternal obesity and metabolic (dysfunction) associated fatty liver disease in pregnancy: a comprehensive narrative review Bianca M. Leca, Lukasz Lagojda, Chris Kite, Emmanouil Karteris, Eva Kassi, Harpal S. Randeva, Ioannis Kyrou Expert Review of Endocrinology & Metabolism.2024; 19(4): 335. CrossRef
Non-alcoholic fatty liver disease and pregnancy T. P. Shevlyukovа, I. A. Bulatovа Perm Medical Journal.2024; 41(3): 77. CrossRef
Novel insights into causal effects of maternal nonalcoholic fatty liver disease on adverse pregnancy outcomes: evidence from Human Genetics and Mendelian Randomization Study Qiuyan Luo, Guoting Liu, Qiulan Li, Jinghong Lu, Wenjing Zheng, Yukui Huang, Cun Li European Journal of Clinical Nutrition.2024; 78(12): 1041. CrossRef
Study on the mechanism of Shenling Baizhu powder on the pathogenesis of pregnancy complicated with non-alcoholic fatty liver, based on PI3K/AKT/mTOR signal pathway Yao Le, Zhijun Wang, Qian Zhang, Ling Miao, Xiaohong Wang, Guorong Han European Journal of Histochemistry.2024;[Epub] CrossRef
Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives Yang Zhang, Yifan Bu, Rui Zhao, Cheng Han Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
Experimental model of non-alcoholic fatty liver disease in pregnant rats to evaluate the effectiveness of therapy Elena V. Mozgovaia, Marina A. Kryshnia, Alexandra А. Blazhenko, Alina А. Nuzhnova, Gulrukhsor Tolibova, Tatyana G. Tral, Janna N. Toumasova, Andrey V. Korenevsky, Irina V. Zalozniaia, Victoria S. Ganzhina, Olesya N. Bespalova Journal of obstetrics and women's diseases.2024; 73(6): 116. CrossRef
Evaluation of Liver Disease in Pregnancy Gres Karim, Dewan Giri, Tatyana Kushner, Nancy Reau Clinics in Liver Disease.2023; 27(1): 133. CrossRef
Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study Seung Mi Lee, Geum Joon Cho, Won Young Wi, Errol R. Norwitz, Bo Kyung Koo, Jeesun Lee, Young Mi Jung, Soo Heon Kwak, Chan-Wook Park, Jong Kwan Jun, Sae Kyung Joo, Min-Jeong Oh, Won Kim, Joong Shin Park Hepatology International.2023; 17(2): 367. CrossRef
Elevated Hepatic Steatosis Index is Associated with the Development of Adverse Maternal, but Not Adverse Neonatal, Outcomes: A Retrospective Cohort Study Thora Y Chai, Karen Byth, Jacob George, Dharmintra Pasupathy, N Wah Cheung International Journal of Women's Health.2023; Volume 15: 589. CrossRef
Dietary intake of pregnant women with non-alcoholic fatty liver disease: A case-control study Lucas A. Chagas, Maria R. Torloni, Victor H.S. Sanchez, Bianca A. Pititto, Patrícia M. Dualib, Rosiane Mattar Clinical Nutrition ESPEN.2023; 57: 630. CrossRef
Impact of neighbourhood-level social determinants of health on healthcare utilisation and perinatal outcomes in pregnant women with NAFLD cirrhosis: a population-based study in Ontario, Canada Mary B Holdsworth, Maya Djerboua, Jennifer A Flemming Journal of Epidemiology and Community Health.2023; 77(12): 809. CrossRef
Non-alcoholic steatohepatitis in pregnancy: a case report Jonathan Cordivani, Lamy Clotilde, Boulvain Michel, Riera Catherine Bulletin of the National Research Centre.2023;[Epub] CrossRef
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time? Seung Mi Lee, Won Kim Clinical and Molecular Hepatology.2022; 28(1): 47. CrossRef
Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment Ja-Young Kwon Clinical and Molecular Hepatology.2022; 28(1): 50. CrossRef
Autoimmune hepatitis (AIH) is an organ specific autoimmune condition which can manifest at any age of life. The heterogeneous nature of this condition means that great variation can be seen in severity, progression of disease and response to treatment within this patient group. Since the 1980s prednisolone and azathioprine have been used for induction and remission of the disease and remain the mainstay of treatment. Other immunosuppressive agents have been employed in difficult to treat cases. While there is less published data regarding these agents compared with the conventional treatments of steroid and azathioprine, there is mounting evidence to support the use of mycophenolate mofetil as a second-line agent. The calcineurin inhibitors, though less studied, additionally show promise. More data is needed on the use of biological agents in refractory disease. This review focuses on our centre’s approach to treatment of AIH in the context of a contemporary review of the literature.
Citations
Citations to this article as recorded by
Comment on “Paediatric-onset autoimmune liver disease: Insights from a monocentric experience” Qateen Zahra, Javeria Zulfiqar Cheema, Muhammad Rafay Shahzad Cheema Digestive and Liver Disease.2025; 57(3): 797. CrossRef
The safety and efficacy of rituximab in autoimmune hepatitis: a systematic review and quality assessment Mohammad Amin Habibi, Fatemeh Aghayee, Mohammad Sina Mirjani, Mohammad Reza Karimifar, Mohammad Reza Ahmadi, Seyed Mohammad Eazi, Poriya Minaee, Mohammad Reza Pashaei, Ahmad Hormati, Mohammad Mahdi Akbari Aleagha, Sajjad Ahmadpour European Journal of Gastroenterology & Hepatology.2025; 37(10): 1097. CrossRef
Autoimmune hepatitis presenting with concomitant chronic pancreatitis Dhruv Patel, Ahmed Salem, Brooke Kania, William Lewis, Anas Mahmoud, Mina Alkomos Radiology Case Reports.2023; 18(9): 2871. CrossRef
Pharmacokinetic/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis Artur Świerczek, Bartosz Pomierny, Elżbieta Wyska, William J. Jusko The Journal of Pharmacology and Experimental Therapeutics.2022; 381(2): 151. CrossRef
Historical aspects and current understanding of autoimmune hepatitis. When is liver transplantation indicated? (Review) I. M. Iljinsky, O. M. Tsirulnikova Russian Journal of Transplantology and Artificial Organs.2022; 24(2): 39. CrossRef
Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases Jilu Zhang, Alan Hodges, Shu-Hsia Chen, Ping-Ying Pan Cellular Immunology.2021; 362: 104300. CrossRef
PK/PD Modeling of the PDE7 Inhibitor—GRMS-55 in a Mouse Model of Autoimmune Hepatitis Artur Świerczek, Hanna Plutecka, Marietta Ślusarczyk, Grażyna Chłoń-Rzepa, Elżbieta Wyska Pharmaceutics.2021; 13(5): 597. CrossRef
Rescue of autoimmune hepatitis by soluble MHC class II molecules in an altered concanavalin A‐induced experimental model Katerina Bakela, Maria Georgia Dimitraki, Evangelia Skoufa, Irene Athanassakis Animal Models and Experimental Medicine.2020; 3(3): 264. CrossRef
Autoimmune Hepatitis and Stellate Cells: An Insight into the Role of Autophagy Shahram Golbabapour, Kamran Bagheri-Lankarani, Saeid Ghavami, Bita Geramizadeh Current Medicinal Chemistry.2020; 27(35): 6073. CrossRef
An intensive medical care network led to successful living-donor liver transplantation in late-onset hepatic failure with disseminated Staphylococcus aureus infection Rie Kure, Natsumi Uehara, Kazuaki Inoue, Tomomi Kogiso, Kazuhisa Kodama, Makiko Taniai, Katsutoshi Tokushige, Masayuki Nakano, Hiroto Egawa, Masakazu Yamamoto Clinical Journal of Gastroenterology.2019; 12(2): 112. CrossRef
Inside autoimmune liver disease Richard L. Pullen, Patricia Francis-Johnson Nursing Made Incredibly Easy!.2019; 17(1): 40. CrossRef
Methylprednisolone Decreases Mitochondria-Mediated Apoptosis and Autophagy Dysfunction in Hepatocytes of Experimental Autoimmune Hepatitis Model via the Akt/mTOR Signaling Xiaoli Fan, Ruoting Men, Haoran Wang, Mengyi Shen, Tingting Wang, Tinghong Ye, Xuefeng Luo, Li Yang Frontiers in Pharmacology.2019;[Epub] CrossRef
Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group Nwe Ni Than, James Hodson, Daniel Schmidt-Martin, Richard Taubert, Rebecca E. Wawman, Meemee Botter, Nishant Gautam, Kilian Bock, Rebecca Jones, Gautham D Appanna, Andrew Godkin, Aldo J. Montano-Loza, Frank Lammert, Christoph Schramm, Michael P. Manns, Ma JHEP Reports.2019; 1(6): 437. CrossRef
Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil F. Fioredda, E. Cappelli, A. Mariani, A. Beccaria, E. Palmisani, A. Grossi, I. Ceccherini, R. Venè, C. Micalizzi, M. Calvillo, F. Pierri, I. Mancini, F. Peyvandi, F. Corsolini, C. Dufour, M. Miano Blood Advances.2019; 3(21): 3432. CrossRef
Transient elastography to assess liver stiffness in patients with inflammatory bowel disease Berrie Meijer, Charlotte K. van Everdingen, Dewkoemar Ramsoekh, Catherine Stedman, Christopher M.A. Frampton, Chris J.J. Mulder, Gerd Bouma, Nanne K.H. de Boer, Richard B. Gearry Digestive and Liver Disease.2018; 50(1): 48. CrossRef
Rheumatic Manifestations in Autoimmune Liver Disease Carlo Selmi, Elena Generali, Merrill Eric Gershwin Rheumatic Disease Clinics of North America.2018; 44(1): 65. CrossRef
Current and future perspectives in autoimmune hepatitis Eleni Theocharidou, Michael A Heneghan British Journal of Hospital Medicine.2018; 79(3): 151. CrossRef
A RARE CASE OF CROHN DISEASE COMPLICATED WITH STEROID MONOTHERAPY-RELATED RETROPHARYNGEAL ABSCESS AND INITIALLY MISINTERPRETED PYODERMA GANGRENOSUM DEVELOPMENT Michael Doulberis, Jörg Dähn, Jannis Kountouras, Volker Maier, Arthur Helbling, Patrick Dubach Gastroenterology Nursing.2018; 41(4): 347. CrossRef
Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis Feng‑Bin Lu, En‑De Hu Hu, Lan‑Man Xu, Yi‑Bing Hu, Lu Chen, Jin‑Lu Wu, Hui Li, Da‑Zhi Chen, Yong‑Ping Chen Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Undiagnosed autoimmune hepatitis causing prolonged mechanical ventilation DavidW Mattingley, ThomasJ Papadimos International Journal of Critical Illness and Injury Science.2018; 8(3): 179. CrossRef
First
Prev
